SBIR-STTR Award

Cloning and Expression ff Full Length Human Orfs
Award last edited on: 6/12/08

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$870,937
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
James P Hoeffler

Company Information

Life Technologies (AKA: Invitrogen Corporation)

5791 Van Allen Way
Carlsbad, CA 92008
   (760) 603-7200
   tech_service@invitrogen.com
   www.invitrogen.com
Location: Multiple
Congr. District: 49
County: San Diego

Phase I

Contract Number: 1R44CA080224-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1998
Phase I Amount
$98,525
Gene cloning and expression are enabling technologies linking genomics to functional genomics. Together, they allow scientists to convent the genetic information from a genome into proteins, the functional units of life. Invitrogen's cloning and expression vectors are similar to an operating system for conversion of genetic information into functional units via cellular hardware. We have recently developed an automated cloning and expression system built around several of our patents and exclusive licenses. We will use this system to clone full-length human cDNAs into a mammalian expression vector to allow functional characterization of the gene products. The application and research plan will be divided into 3 separate areas of focus. The full-length human cDNAs generated by each of the strategies employed in these focus areas will be cloned into expression plasmids, sequenced, and expressed in CHO cells to verify integrity. The research plan is designed to focus on the full- length sequences in existing databases to guide template assembly and RT-PCR-based strategies of full-length template acquisition as a first- level strategy, and then utilize the existing EST homology criteria to prioritize the acquisition of the unknown 5' ends of cancer-related CDNAsProposed Commercial Application:Marketing of the cloned cancer-related genes will involve a strategy of quickly bringing to market the first and largest collection the full- length cancer-related genes in expression (and other) vectors. Marketing of these genes will include the full range of Invitrogen's promotional tactics such as: 1. Advertisements in scientific journals and publications 2. Publication of articles in Invitrogen's newsletter Expressions (6 issues annually) 3. Internet access to a searchable database of cloned genes 4. Directed promotional mailings to target audiences in industry and academia 5. Public relations and press releases 6. Trade shows 7. Scientific seminars, and workshops

Thesaurus Terms:
complementary DNA, gene expression, molecular cloning nucleic acid sequence, plasmid CHO cell, human genetic material tag, polymerase chain reaction, tissue /cell culture, transfection vectorNATIONAL CANCER INSTITUTE

Phase II

Contract Number: 4R44CA080224-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1999
(last award dollars: 2000)
Phase II Amount
$772,412

Gene cloning and expression are enabling technologies linking genomics to functional genomics. Together, they allow scientists to convent the genetic information from a genome into proteins, the functional units of life. Invitrogen's cloning and expression vectors are similar to an operating system for conversion of genetic information into functional units via cellular hardware. We have recently developed an automated cloning and expression system built around several of our patents and exclusive licenses. We will use this system to clone full-length human cDNAs into a mammalian expression vector to allow functional characterization of the gene products. The application and research plan will be divided into 3 separate areas of focus. The full-length human cDNAs generated by each of the strategies employed in these focus areas will be cloned into expression plasmids, sequenced, and expressed in CHO cells to verify integrity. The research plan is designed to focus on the full- length sequences in existing databases to guide template assembly and RT-PCR-based strategies of full-length template acquisition as a first- level strategy, and then utilize the existing EST homology criteria to prioritize the acquisition of the unknown 5' ends of cancer-related CDNAs PROPOSED COMMERCIAL APPLICATION: Marketing of the cloned cancer-related genes will involve a strategy of quickly bringing to market the first and largest collection the full- length cancer-related genes in expression (and other) vectors. Marketing of these genes will include the full range of Invitrogen's promotional tactics such as: 1. Advertisements in scientific journals and publications 2. Publication of articles in Invitrogen's newsletter Expressions (6 issues annually) 3. Internet access to a searchable database of cloned genes 4. Directed promotional mailings to target audiences in industry and academia 5. Public relations and press releases 6. Trade shows 7. Scientific seminars, and workshops.

Thesaurus Terms:
complementary DNA, gene expression, molecular cloning nucleic acid sequence, plasmid CHO cell, human genetic material tag, polymerase chain reaction, tissue /cell culture, transfection vector